Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733013 · ClinicalTrials.gov registry record
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
A clinical trial of Thyroid Cancer and Thyroid, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05733013: Recruiting study of Thyroid Cancer and Thyroid, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05733013 is a study of Thyroid Cancer and Thyroid that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05733013, a study of Thyroid Cancer and Thyroid, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
Primary Outcome
The primary objective of this protocol is to prospectively collect data on patients with radio-iodine refractory thyroid cancer or patients unlikely to respond to radioactive iodine prior, during and after initiation of redifferentiating agents used as part of routine clinical care with or without radioactive iodine treatment.
Conditions Studied
Interventions
- OTHER Surveillance Visit
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2028-02-07 |
What NCT05733013 shows while recruiting
NCT05733013 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Surveillance Visit is the first listed.
NCT05733013 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05733013 about?
NCT05733013 is a clinical study titled "A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer". The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
What is the current status of trial NCT05733013?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-02-07. Estimated completion is 2028-02-07.
What conditions does trial NCT05733013 study?
This clinical trial studies the following conditions: Thyroid Cancer, Thyroid, Refractory Thyroid Cancer.
What interventions are being tested in trial NCT05733013?
The interventions under investigation include: Surveillance Visit (OTHER).
Who is sponsoring clinical trial NCT05733013?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733013 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05733013's enrollment target sits among peer trials
100 17th of 46 higher than 28 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI